- Previous Close
2.4800 - Open
2.5100 - Bid 2.4600 x 100
- Ask 2.5800 x 100
- Day's Range
2.5100 - 2.5499 - 52 Week Range
2.3350 - 6.0550 - Volume
99,618 - Avg. Volume
1,804,556 - Market Cap (intraday)
744.032M - Beta (5Y Monthly) 0.37
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5300 - Earnings Date Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.43
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
www.abcellera.comRecent News: ABCL
View More
Performance Overview: ABCL
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABCL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABCL
View MoreValuation Measures
Market Cap
730.77M
Enterprise Value
132.47M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
21.89
Price/Book (mrq)
0.66
Enterprise Value/Revenue
4.01
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-11.41%
Return on Equity (ttm)
-13.30%
Revenue (ttm)
33.05M
Net Income Avi to Common (ttm)
-153.3M
Diluted EPS (ttm)
-0.5300
Balance Sheet and Cash Flow
Total Cash (mrq)
670.36M
Total Debt/Equity (mrq)
6.49%
Levered Free Cash Flow (ttm)
-133.39M
Research Analysis: ABCL
View MoreCompany Insights: ABCL
ABCL does not have Company Insights
Research Reports: ABCL
View MoreDaily – Vickers Top Buyers & Sellers for 08/30/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 05/30/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/21/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 08/23/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.